{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:15:18Z","timestamp":1740107718548,"version":"3.37.3"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T00:00:00Z","timestamp":1627430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T00:00:00Z","timestamp":1627430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s10067-021-05868-4","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T00:02:45Z","timestamp":1627430565000},"page":"5121-5123","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Is combination of immunosuppressive drugs the answer to reduce glucocorticoid burden in patients with lupus nephritis?"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0499-0641","authenticated-orcid":false,"given":"Kunal","family":"Chandwar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sapan","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,28]]},"reference":[{"issue":"8","key":"5868_CR1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJM198408233110802","volume":"311","author":"JE Balow","year":"1984","unstructured":"Balow JE, Austin HA 3rd, Muenz LR, Joyce KM, Antonovych TT, Klippel JH, Steinberg AD, Plotz PH, Decker JL (1984) Effect of treatment on the evolution of renal abnormalities in lupus nephritis. N Engl J Med 311(8):491\u2013495. https:\/\/doi.org\/10.1056\/NEJM198408233110802","journal-title":"N Engl J Med"},{"issue":"21","key":"5868_CR2","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1001\/jama.2021.6615","volume":"325","author":"S Furuta","year":"2021","unstructured":"Furuta S, Nakagomi D, Kobayashi Y et al (2021) Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial. JAMA 325(21):2178\u20132187. https:\/\/doi.org\/10.1001\/jama.2021.6615","journal-title":"JAMA"},{"issue":"7","key":"5868_CR3","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne DRW, Merkel PA, Schall TJ, Bekker P, ADVOCATE Study Group (2021) Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 384(7):599\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa2023386","journal-title":"N Engl J Med."},{"issue":"7","key":"5868_CR4","doi-asserted-by":"publisher","first-page":"549","DOI":"10.7326\/0003-4819-125-7-199610010-00003","volume":"125","author":"MF Gourley","year":"1996","unstructured":"Gourley MF, Austin HA III, Scott D, Yarboro CH, Vaughan EM, Muir J, Boumpas DT, Klippel JH, Balow JE, Steinberg AD (1996) Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial. Ann Intern Med 125(7):549\u2013557","journal-title":"Ann Intern Med"},{"issue":"8","key":"5868_CR5","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1002\/art.10461","volume":"46","author":"FA Houssiau","year":"2002","unstructured":"Houssiau FA, Vasconcelos C, D\u2019Cruz D et al (2002) Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46(8):2121\u20132131. https:\/\/doi.org\/10.1002\/art.10461","journal-title":"Arthritis Rheum"},{"doi-asserted-by":"crossref","unstructured":"Furie R, Aroca G, Alvarez A, Fragoso-Loyo H, Zuta Santillan E, Rovin B, Brunetta P, Schindler T, Hassan I, Cascino M, Garg J, Malvar A (2020) Two-year results from a randomized, controlled study of obinutuzumab for proliferative lupus nephritis [abstract]. Arthritis Rheumatol 72 (suppl 10)","key":"5868_CR6","DOI":"10.1136\/lupus-2020-eurolupus.46"},{"key":"5868_CR7","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G et al (2020) Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 383:1117\u20131128. https:\/\/doi.org\/10.1056\/NEJMoa2001180","journal-title":"N Engl J Med"},{"issue":"10289","key":"5868_CR8","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","volume":"397","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Teng YKO, Ginzler EM et al (2021) Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial [published correction appears in Lancet. 2021 May 29;397(10289):2048]. Lancet 397(10289):2070\u20132080. https:\/\/doi.org\/10.1016\/S0140-6736(21)00578-X","journal-title":"Lancet"},{"issue":"8","key":"5868_CR9","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1136\/annrheumdis-2012-202844","volume":"72","author":"MB Condon","year":"2013","unstructured":"Condon MB, Ashby D, Pepper RJ et al (2013) Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 72(8):1280\u20131286. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202844","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"5868_CR10","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1056\/NEJMoa1803537","volume":"382","author":"M Walsh","year":"2020","unstructured":"Walsh M, Merkel PA, Peh CA, PEXIVAS Investigators et al (2020) Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 382(7):622\u2013631. https:\/\/doi.org\/10.1056\/NEJMoa1803537","journal-title":"N Engl J Med."},{"issue":"14","key":"5868_CR11","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1177\/0961203311418269","volume":"20","author":"M Zeher","year":"2011","unstructured":"Zeher M, Doria A, Lan J et al (2011) Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus 20(14):1484\u20131493. https:\/\/doi.org\/10.1177\/0961203311418269","journal-title":"Lupus"},{"key":"5868_CR12","doi-asserted-by":"publisher","first-page":"373","DOI":"10.4103\/ijn.IJN_299_18","volume":"29","author":"J Bharati","year":"2019","unstructured":"Bharati J, Rathi M, Ramachandran R et al (2019) Comparison of two steroid regimens in induction therapy of proliferative lupus nephritis: a randomized controlled trial. Indian J Nephrol 29:373\u2013375","journal-title":"Indian J Nephrol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05868-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05868-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05868-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T01:06:02Z","timestamp":1637197562000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05868-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,28]]},"references-count":12,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5868"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05868-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2021,7,28]]},"assertion":[{"value":"29 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}